ACRV Stock Overview
A clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
Acrivon Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$6.51 |
| 52 Week High | US$11.90 |
| 52 Week Low | US$3.19 |
| Beta | 0.78 |
| 1 Month Change | 3.33% |
| 3 Month Change | -24.04% |
| 1 Year Change | 83.90% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -60.88% |
Recent News & Updates
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Dec 12We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17
Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Recent updates
Acrivon Therapeutics: Endometrial Cancer Data Continues To Justify A Nascent Thesis
Dec 12We're Not Very Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Rate
Nov 17Breaking Down Acrivon: Deep Dive Into Revenue, Profitability, And Prospects
Sep 18Is Acrivon Therapeutics (NASDAQ:ACRV) In A Good Position To Invest In Growth?
Jul 17Here's Why We're Not Too Worried About Acrivon Therapeutics' (NASDAQ:ACRV) Cash Burn Situation
Mar 29Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Oct 05Acrivon Therapeutics (NASDAQ:ACRV) Is In A Good Position To Deliver On Growth Plans
Jun 22We Think Acrivon Therapeutics (NASDAQ:ACRV) Can Afford To Drive Business Growth
Feb 22Shareholder Returns
| ACRV | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 12.4% | 3.5% | 0.6% |
| 1Y | 83.9% | 2.9% | 22.4% |
Return vs Industry: ACRV exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: ACRV exceeded the US Market which returned 22.4% over the past year.
Price Volatility
| ACRV volatility | |
|---|---|
| ACRV Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 11.4% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 18.8% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: ACRV's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: ACRV's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2018 | 60 | Peter Blume-Jensen | www.acrivon.com |
Acrivon Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in developing oncology medicines for the patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company’s Acrivon Predictive Precision Proteomics, a precision medicine platform enables the creation of drug specific proprietary OncoSignature companion diagnostics that are used to identify the patients to benefit from its drug candidates. Its lead clinical candidate is ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2, which is in Phase II clinical trial across various tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer.
Acrivon Therapeutics, Inc. Fundamentals Summary
| ACRV fundamental statistics | |
|---|---|
| Market cap | US$217.02m |
| Earnings (TTM) | -US$76.98m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-2.6x
P/E RatioIs ACRV overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ACRV income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$76.98m |
| Earnings | -US$76.98m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.47 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did ACRV perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/02/06 23:55 |
| End of Day Share Price | 2025/02/06 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acrivon Therapeutics, Inc. is covered by 13 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Etzer Darout | BMO Capital Markets Equity Research |
| Evan Seigerman | BMO Capital Markets Equity Research |
| Li Wang Watsek | Cantor Fitzgerald & Co. |